ArticleProbiotics and antimicrobial proteins2026
Investigation of Production and Anti-Diabetic Effects of Kefir Enriched with Paraprobiotics.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigated the physicochemical, microbiological, and consumer acceptance of kefir with and without paraprobiotics (inactivated kefir starter culture) and evaluated its effects on streptozotocin (STZ)-induced type 1 diabetes mellitus (T1DM) in Wistar rats. The pH, titratable acidity, and exopolysaccharide (EPS) values of the kefir samples ranged from 3.52 to 4.52, 0.71% to 1.58%, and 1.02 g/kg to 1.63 g/kg, respectively. The exopolysaccharide content of kefir samples produced by adding an inactive kefir starter culture before and after fermentation was higher than that of the control samples. The apparent viscosity values, flow behaviour index values, and consistency coefficient values of the kefir samples varied between 0.09 and 0.16 Pa·s, between 0.21 and 0.34, and between 1.44 and 2.79 Pa·sⁿ, respectively. During the storage period, the highest taste and overall acceptability scores were observed in kefir samples produced by adding inactive starter kefir culture before fermentation. In blood glucose measurements, although an increase was observed in the groups given kefir samples at the beginning, the values approached those of the control group by the end of the experiment. In the oral glucose tolerance test (OGTT) results, a significant reduction in glucose levels was determined in the kefir groups compared to the T1DM group, while no statistically significant difference was observed among the kefir groups. These findings indicate that kefir, particularly when enriched with inactivated kefir starter culture before fermentation, offers improved textural and sensory profiles. However, the anti-hyperglycaemic potential may be primarily attributed to the kefir matrix, regardless of the addition of paraprobiotics before or after.
Indexed as
Identifiers
42501278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.